FDA approves Sunharbo (asundexian), first factor XIa blocker, to prevent repeat stroke
In the 12,327-patient trial behind the approval, 6.6% of patients on the drug had a stroke, compared with 8.8% on placebo. Gastrointestinal bleeding was more common with the drug.
Key takeaways
- The FDA has approved Sunharbo (asundexian), a 50-milligram pill taken once a day with standard antiplatelet therapy such as aspirin, to lower the risk of another stroke in certain adults.
- It is meant for adults with a recent ischemic stroke from a clot that did not form in the heart, or a transient ischemic attack, and it is the first approved drug of its kind to block factor XIa.
- In a phase 3 trial of 12,327 patients, 6.6% of patients on asundexian had a stroke, compared with 8.8% on placebo, a 26% lower relative risk.
- Overall major bleeding did not rise significantly, but gastrointestinal bleeding was more common, and patients older than 75 had more major bleeding in the first 90 days.
- For crews: the name Sunharbo or asundexian on a medication list means the patient is taking a factor XIa inhibitor along with an antiplatelet drug.
The U.S. Food and Drug Administration has approved Sunharbo (asundexian), a once-daily pill to lower the chance of a second stroke in certain adults. FOX 5 Atlanta and Yahoo News reported the approval on Nov. 14, 2026, based on an FDA announcement. Neither report gives the exact date the FDA acted. [1] [2]
Patients take one 50-milligram tablet a day along with standard antiplatelet therapy, such as aspirin. The reports describe the FDA release as covering adults who recently had either an ischemic stroke from a clot that did not start in the heart or a transient ischemic attack (TIA). [1]
According to the reports, Sunharbo is the first approved drug of its type to block factor XIa, a blood protein involved in forming clots. Bayer makes asundexian and paid for the trial that supported the approval. [1] [2]
What the records show
The approval rests on a phase 3 randomized trial of 12,327 patients in 37 countries. Every participant had recently had a non-cardioembolic ischemic stroke or a high-risk TIA. Patients took either asundexian 50 milligrams daily or a placebo, and both groups also received antiplatelet therapy. Follow-up lasted about 14.2 months. The results were published in The New England Journal of Medicine on Nov. 9. [1]
The reported results:
| Outcome | Asundexian plus antiplatelet | Placebo plus antiplatelet |
|---|---|---|
| Stroke | About 6.6% | 8.8% |
| Death from heart-related causes, heart attack or stroke (combined) | 9.2% | 11.1% |
| Death from any cause | 10.5% | 12.3% |
The drug group's risk of ischemic stroke was 26% lower in relative terms than the placebo group's. [1] [2]
On safety, the reports say major bleeding did not increase significantly across the whole trial. Some groups did fare worse. Gastrointestinal bleeding was more frequent on asundexian. Patients over 75 had a higher risk of major bleeding during the first 90 days of treatment. [1] [2]
Dr. Richard Kovacs, a cardiologist at Indiana University School of Medicine and chief medical officer of the American College of Cardiology, described the mechanism to Fox News Digital: "This blocks a very specific protein that's part of the cascade of blood clotting." He also said the drug "doesn't completely eliminate the risk of a second stroke." [2]
Why it matters for clinicians
This is a new drug class for preventing a second stroke. Patients who take it will be on two drugs that work against clotting: asundexian and an antiplatelet agent. The bleeding signals in the trial were more GI bleeding and more early major bleeding in patients over 75. Those groups are where the reported safety concerns center. [1]
Timing also matters. Kovacs said that in the trial, the drug "was given very soon after the stroke – within 72 hours." He added that the decision often comes "early on, often in the hospital." [2]
The approved population is narrow. Kovacs said the drug "is not for patients who have had strokes due to atrial fibrillation or due to a valve problem in their heart." The trial also excluded patients with certain heart conditions and patients with more severe strokes. [1] [2]
Prehospital crews may start seeing Sunharbo or asundexian on medication lists of patients who have had a non-cardioembolic stroke or TIA.
Context
The reports cite the Centers for Disease Control and Prevention: more than 795,000 people in the United States have a stroke each year. About 185,000 of them have had a stroke before. The reports also say about one in four stroke survivors has another stroke within five years. [1]
Kovacs said atherosclerosis caused the stroke in many of the patients the drug targets. [1]
What the records do not tell us
- The exact FDA approval date, the full prescribing label, and the label's contraindications and warnings. The packet contains only news reports describing the FDA announcement, not the FDA document itself.
- Whether there is a reversal agent or a specific way to manage bleeding in patients taking asundexian.
- Absolute major-bleeding and GI-bleeding rates for each group. The reports describe the bleeding findings only in general terms.
- Price, insurance coverage, and when the drug will reach pharmacies.
- Long-term safety and effectiveness. The researchers said treatment averaged about 14 months, which leaves those questions open.
- Any comment from Bayer. The reports quote no one from the company.
What to watch
According to the reports, the researchers said longer studies are needed in older adults, underrepresented populations, and people with more severe strokes. The reports give no timeline for those studies. [1]
Questions readers ask
What is Sunharbo (asundexian) approved for?
The FDA approved Sunharbo to help prevent another stroke in adults who recently had an ischemic stroke from a clot that did not start in the heart, or a transient ischemic attack. It is taken with standard antiplatelet therapy such as aspirin.
How well does asundexian prevent a second stroke?
In a phase 3 trial of 12,327 patients, about 6.6% of patients on asundexian had a stroke, compared with 8.8% on placebo. That is a 26% lower relative risk of ischemic stroke over about 14.2 months.
Does asundexian increase bleeding risk?
Overall major bleeding did not rise significantly in the trial. Gastrointestinal bleeding was more frequent, and patients older than 75 had a higher risk of major bleeding in the first 90 days.
Can patients with atrial fibrillation take Sunharbo?
Dr. Richard Kovacs of the American College of Cardiology said the drug is not for patients whose strokes were caused by atrial fibrillation or a heart valve problem. The trial also excluded patients with certain heart conditions or more severe strokes.
Sources
- FOX 5 Atlanta: FDA approves daily pill shown to cut repeat stroke risk by 26% (Nov. 14, 2026) (2026-11-14). fox5atlanta.com/news/fda-approves-daily-pill-shown-cut-repeat-stroke-r
- Yahoo News: FDA approves daily pill shown to cut repeat stroke risk by 26% (Nov. 14, 2026) (2026-11-14). yahoo.com/news/science/articles/fda-approves-daily-pill-shown-15434433
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.


